Cargando…
Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
The treatment paradigm for urothelial carcinoma (UC), a common genitourinary cancer, has significantly expanded in recent years. Enfortumab vedotin, a Nectin-4–targeted antibody-drug conjugate, was recently approved by the U.S. Food & Drug Administration for patients with advanced or metastatic...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press LLC
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863123/ https://www.ncbi.nlm.nih.gov/pubmed/33604101 http://dx.doi.org/10.6004/jadpro.2020.11.4.8 |